AR065335A1 - Combinaciones de agentes terapeuticos para el tratamiento de cancer - Google Patents
Combinaciones de agentes terapeuticos para el tratamiento de cancerInfo
- Publication number
- AR065335A1 AR065335A1 ARP080100618A ARP080100618A AR065335A1 AR 065335 A1 AR065335 A1 AR 065335A1 AR P080100618 A ARP080100618 A AR P080100618A AR P080100618 A ARP080100618 A AR P080100618A AR 065335 A1 AR065335 A1 AR 065335A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- kinase
- tyrosine
- kinase inhibitor
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Combinacion que comprende la N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-iI)-etil]-amino]-metil]-fenil]-2E-2-propenamida; y uno o más agentes farmacéuticamente activos; a composiciones farmacéuticas que comprenden esta combinacion; a métodos detratamiento que comprenden esta combinacion; a procesos para elaborar dicha combinacion; y a un paquete comercial que comprende la combinacion mencionada. Reivindicacion 1: Una combinacion de: (a) N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)-etiI]-amino]-metil]-fenil}-2E-2-propenamida; y (b) uno o más agentes farmacéuticamente activos seleccionados a partir del grupo que consiste en: Un inhibidor de la enzima convertidora de angiotensina, Un inhibidor de la cinasa de adenosina; Un adyuvante;Un antagonista de la corteza adrenal; Un inhibidor de la senda de AKT; Un agente alquilante; Un inhibidor de angiogénesis; Un esteroide angiostático; Un anti-androgeno; Un anti-estrogeno; Un agente anti-hipercalcemia; Un compuesto anti-leucémico; Unanti-metabolito; Un anticuerpo anti-proliferativo; Un inductor de apoptosis; Un antagonista del receptor AT1; Un inhibidor de la cinasa aurora; Un inhibidor de aromatasa; Un modificador de la respuesta biologica; Un bisfosfonato; Un inhibidor de lacinasa de tirosina de Bruton (BTK); Un inhibidor de calcineurina; Un inhibidor de la cinasa CaM II; Un inhibidor de la fosfatasa de tirosina CD45; Un inhibidor de la fosfatasa CDC25; Un inhibidor de CYP3A4; Un inhibidor de la cinasa CHK; Uncompuesto que dirige/reduce una actividad de cinasa de proteína o de lípido, o una actividad de fosfatasa de proteína o de lípido, un compuesto antiangiogénico adicional, o un compuesto que induce los procesos de la diferenciacion celular; Un agentede control para regular genisteína, olomucina, y/o tirfostinas; Un inhibidor de ciclo-oxigenasa; Un inhibidor de la cinasa cRAF; Un inhibidor de la cinasa dependiente de ciclina; Un inhibidor de la proteasa de cisteína; Un intercalador de ADN; Unrompedor de cadena de ADN; Un inhibidor de la ligasa E3; Un enlazador de EDG; Una hormona endocrina; Compuestos que dirigen, reducen, o inhiben la actividad de la familia del factor de crecimiento epidérmico; Un inhibidor de la cinasa de tirosinareceptora del factor de crecimiento epidérmico, y receptora del factor de crecimiento derivado de plaquetas; Un inhibidor de farnesil-transferasa; Un inhibidor de la cinasa Flk-1; Un compuesto que dirige, reduce, o inhibe la actividad de Flt-3; Unagonista de gonadorelina; Un inhibidor de la cinasa de sintasa de glicogeno-3 (GSK3); Un inhibidor de heparanasa; Un agente utilizado en el tratamiento de malignidades hematologicas; Un inhibidor de la desacetilasa de histona (HDAC); Un inhibidor deHSP90; Un implante que contiene corticosteroides; Un inhibidor de la cinasa l-Kappa B-alfa (IKK); Un inhibidor de la cinasa de tirosina receptora de insulina; Un inhibidor de la cinasa de cinasa N-terminal c-Jun (JNK); Un agente de enlace demicrotubulo; Un inhibidor de cinasa de proteína activada por mitogeno (MAP); Un inhibidor de MDM2; Un inhibidor de MEK; Un inhibidor amino-peptidasa de metionina; Un inhibidor del inhibidor de metaloproteinasa de matriz (MMP); Un anticuerpomonoclonal; Un inhibidor de la cinasa de tirosina NGFR; Un inhibidor de la cinasa MAP p38, incluyendo un inhibidor de la cinasa SAPK2/p38; Un inhibidor de la cinasa de tirosina p56; Un inhibidor de la cinasa de tirosina receptora del factor decrecimiento derivado de plaquetas; Un inhibidor de la cinasa de fosfatidil-inositol-3; Un inhibidor de fosfatasa; Terapia fotodinámica; Un agente de platino; Un inhibidor de la fosfata de proteína, incluyendo un inhibidor de PP1 y PP2, y uninhibidor de la fosfatasa de tirosina; Un inhibidor de la cinasa C de proteína, y un inhibidor de la cinasa delta de la cinasa C de proteína; Un inhibidor de la síntesis de poliamina; Un inhibidor de proteasoma; Un inhibidor de PTP1B; Un inhibidorde la cinasa de proteína tirosina, incluyendo un inhibidor de la cinasa de tirosina de la familia SRC; un inhibidor de la cinasa de tirosina Syk; y un inhibidor de la cinasa de tirosina JAK-2 y/o JAK3; Un inhibidor de las isoformas oncogénicas Ras;Un retinoide; Un inhibidor de la reductasa de ribonucleotido; Un inhibidor de elongacion de la polimerasa de ARN II; Un inhibidor de la descarboxilasa de S-adenosil metionina; Un inhibidor de la cinasa de serina/treonina; Un compuesto que dirige,reduce, o inhibe la actividad/funcion de la cinasa mTOR de serina/treonina; Un antagonista del receptor de sornatostatina; Un inhibidor de la biosíntesis de esterol; Un inhibidor de telomerasa; Un inhibidor de topoisomerasa; Planteamientos que dananlas células tumorales; Un anticuerpo monoclonal del factor de crecimiento endotelial vascular o del receptor del factor de crecimiento endotelial vascular; Un inhibidor de la cinasa de tirosina receptora del factor de crecimiento endotelialvascular; y Un inhibidor de RANKL; y una mezcla de los mismos; para su uso simultáneo, concurrente, separado, o en secuencia en la prevencion o el tratamiento de una enfermedad proliferativa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89000507P | 2007-02-15 | 2007-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065335A1 true AR065335A1 (es) | 2009-06-03 |
Family
ID=39560929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100618A AR065335A1 (es) | 2007-02-15 | 2008-02-13 | Combinaciones de agentes terapeuticos para el tratamiento de cancer |
Country Status (21)
Country | Link |
---|---|
US (7) | US20100069458A1 (es) |
EP (3) | EP2120900A2 (es) |
JP (1) | JP2010519209A (es) |
KR (1) | KR20090110913A (es) |
CN (1) | CN101626758A (es) |
AR (1) | AR065335A1 (es) |
AU (1) | AU2008216327A1 (es) |
BR (1) | BRPI0807812A2 (es) |
CA (1) | CA2677651A1 (es) |
CL (1) | CL2008000470A1 (es) |
CO (1) | CO6220928A2 (es) |
EC (1) | ECSP099576A (es) |
IL (1) | IL200193A0 (es) |
MA (1) | MA31205B1 (es) |
MX (1) | MX2009008584A (es) |
PE (1) | PE20090519A1 (es) |
RU (1) | RU2009134223A (es) |
TN (1) | TN2009000344A1 (es) |
TW (1) | TW200848022A (es) |
WO (1) | WO2008100985A2 (es) |
ZA (1) | ZA200905159B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
EP2117598A2 (en) * | 2007-01-10 | 2009-11-18 | Novartis AG | Formulations of deacetylase inhibitors |
KR20090122218A (ko) | 2007-03-01 | 2009-11-26 | 노파르티스 아게 | 5-(2,4-디히드록시-5-이소프로필-페닐)-4-(4-모르폴린-4-일메틸-페닐)-이속사졸-3-카르복실산 에틸아미드의 산 부가염, 수화물 및 다형체, 및 이들 형태를 포함하는 제제 |
CL2008002786A1 (es) * | 2007-09-20 | 2009-05-15 | Novartis Ag | Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion. |
AU2010203512C1 (en) | 2009-01-08 | 2013-10-17 | Curis, Inc. | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
US8491927B2 (en) | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
CA2795952A1 (en) * | 2010-04-16 | 2011-10-20 | Curis, Inc. | Treatment of cancers having k-ras mutations |
CN102241628B (zh) * | 2010-05-14 | 2015-11-25 | 中国人民解放军总医院 | (2e)-3-苯基-n-[2,2,2-三氯-1-[[(8-喹啉基氨基)硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途 |
MX2020004501A (es) | 2010-06-03 | 2021-11-09 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
KR20130101519A (ko) * | 2010-09-01 | 2013-09-13 | 노파르티스 아게 | Hdac 억제제와 혈소판감소증 약물의 조합물 |
EA022434B9 (ru) | 2011-04-01 | 2016-02-29 | Кьюрис, Инк. | Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент |
JP6363502B2 (ja) * | 2011-04-28 | 2018-07-25 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Hsp90併用療法 |
JP6200884B2 (ja) * | 2011-06-14 | 2017-09-20 | ノバルティス アーゲー | 骨髄増殖性腫瘍などの癌の治療におけるパノビノスタットおよびルキソリチニブの組合せ |
WO2013003629A2 (en) * | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Methods and compositions for inhibition of bone resorption |
CN102949722A (zh) * | 2011-08-26 | 2013-03-06 | 中国医学科学院放射医学研究所 | 基于p38抑制剂和细胞生长因子的新颖药物组合物 |
CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
AU2013234955A1 (en) | 2012-03-23 | 2014-11-13 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
KR20180088926A (ko) | 2012-07-24 | 2018-08-07 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
US10106778B2 (en) | 2012-11-08 | 2018-10-23 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
MX2015011733A (es) * | 2013-03-14 | 2016-04-25 | Pharmacyclics Llc | Combinaciones de inhibidores de la tirosina quinasa de bruton e inhibidores de cyp3a4. |
AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
EP3137085A4 (en) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
AU2015296968A1 (en) * | 2014-06-10 | 2017-02-02 | University Of South Carolina | Methods and compositions for treatment of HER-positive cancers |
MA41544A (fr) * | 2015-02-19 | 2017-12-26 | Novartis Ag | Dosages de panobinostat pour le traitement du myélome multiple |
KR20240115925A (ko) | 2016-07-29 | 2024-07-26 | 얀센 파마슈티카 엔브이 | 전립선암의 치료 방법 |
KR101941045B1 (ko) * | 2017-08-09 | 2019-01-22 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 약학적 조성물 |
KR101988124B1 (ko) * | 2017-08-31 | 2019-06-11 | 사회복지법인 삼성생명공익재단 | 암 연관 섬유아세포 표적용 약학적 조성물 |
JP2021534124A (ja) | 2018-08-10 | 2021-12-09 | ナビール ファーマ,インコーポレイティド | 癌治療用ptpn11(shp2)阻害剤としての6−(4−アミノ−3−メチル−2−オキサ−8−アザスピロ[4.5]デカン−8−イル)−3−(2,3−ジクロロフェニル)−2−メチルピリミジン−4(3h)−オン誘導体及び関連化合物 |
CA3112177A1 (en) | 2018-09-11 | 2020-03-19 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
CN115137716A (zh) * | 2021-04-19 | 2022-10-04 | 海军军医大学第一附属医院第二军医大学第一附属医院上海长海医院 | 紫草素及其药学上可接受的盐类在制备预防或治疗绝经后骨质疏松症药物中的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
ATE348110T1 (de) | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
PT817775E (pt) | 1995-03-30 | 2002-01-30 | Pfizer | Derivados de quinazolina |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (pl) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie |
DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
AU716610B2 (en) | 1996-08-30 | 2000-03-02 | Novartis Ag | Method for producing epothilones, and intermediate products obtained during the production process |
AU4141697A (en) | 1996-09-06 | 1998-03-26 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
PT941227E (pt) | 1996-11-18 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
MXPA00008365A (es) | 1998-02-25 | 2002-11-07 | Sloan Kettering Inst Cancer | Sintesis de epotilonas, intermediarios y analogos de las mismas. |
EP1107964B8 (en) | 1998-08-11 | 2010-04-07 | Novartis AG | Isoquinoline derivatives with angiogenesis inhibiting activity |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
BR0009507A (pt) | 1999-03-30 | 2002-01-15 | Novartis Ag | Derivados de ftalazina para o tratamento de doenças inflamatórias |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
ATE352319T1 (de) * | 2001-11-06 | 2007-02-15 | Novartis Pharma Gmbh | Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor |
BRPI0410648A (pt) * | 2003-05-21 | 2006-07-04 | Novartis Ag | combinação de inibidores de histona desacetilase com agentes quimioterápicos |
CN1852737A (zh) * | 2003-09-18 | 2006-10-25 | 诺瓦提斯公司 | 组蛋白脱乙酰酶抑制剂与死亡受体配体的组合 |
EP1743654A1 (en) * | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
PL1912640T3 (pl) * | 2005-08-03 | 2015-11-30 | Novartis Ag | Zastosowanie inhibitora HDAC panobinostatu w leczeniu szpiczaka |
-
2008
- 2008-02-13 EP EP08729719A patent/EP2120900A2/en not_active Withdrawn
- 2008-02-13 EP EP11157791A patent/EP2359818A1/en not_active Withdrawn
- 2008-02-13 PE PE2008000314A patent/PE20090519A1/es not_active Application Discontinuation
- 2008-02-13 JP JP2009549693A patent/JP2010519209A/ja active Pending
- 2008-02-13 BR BRPI0807812-2A patent/BRPI0807812A2/pt not_active Application Discontinuation
- 2008-02-13 MX MX2009008584A patent/MX2009008584A/es not_active Application Discontinuation
- 2008-02-13 AU AU2008216327A patent/AU2008216327A1/en not_active Abandoned
- 2008-02-13 CA CA002677651A patent/CA2677651A1/en not_active Abandoned
- 2008-02-13 KR KR1020097016980A patent/KR20090110913A/ko not_active Application Discontinuation
- 2008-02-13 RU RU2009134223/15A patent/RU2009134223A/ru not_active Application Discontinuation
- 2008-02-13 EP EP12150317A patent/EP2491923A3/en not_active Withdrawn
- 2008-02-13 US US12/526,962 patent/US20100069458A1/en not_active Abandoned
- 2008-02-13 CN CN200880005098A patent/CN101626758A/zh active Pending
- 2008-02-13 WO PCT/US2008/053798 patent/WO2008100985A2/en active Application Filing
- 2008-02-13 AR ARP080100618A patent/AR065335A1/es unknown
- 2008-02-14 TW TW097105218A patent/TW200848022A/zh unknown
- 2008-02-14 CL CL200800470A patent/CL2008000470A1/es unknown
-
2009
- 2009-07-23 ZA ZA200905159A patent/ZA200905159B/xx unknown
- 2009-07-30 IL IL200193A patent/IL200193A0/en unknown
- 2009-08-13 CO CO09085032A patent/CO6220928A2/es not_active Application Discontinuation
- 2009-08-13 EC EC2009009576A patent/ECSP099576A/es unknown
- 2009-08-14 TN TNP2009000344A patent/TN2009000344A1/fr unknown
- 2009-08-31 MA MA32192A patent/MA31205B1/fr unknown
-
2012
- 2012-07-25 US US13/557,731 patent/US20130029927A1/en not_active Abandoned
-
2014
- 2014-12-08 US US14/563,430 patent/US20150094274A1/en not_active Abandoned
-
2016
- 2016-07-28 US US15/222,370 patent/US20170027909A1/en not_active Abandoned
-
2017
- 2017-05-17 US US15/597,718 patent/US20170246147A1/en not_active Abandoned
- 2017-11-14 US US15/812,141 patent/US20180071251A1/en not_active Abandoned
-
2018
- 2018-06-12 US US16/006,137 patent/US20180289670A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170027909A1 (en) | 2017-02-02 |
EP2491923A3 (en) | 2012-12-26 |
TW200848022A (en) | 2008-12-16 |
MX2009008584A (es) | 2009-08-18 |
US20180071251A1 (en) | 2018-03-15 |
MA31205B1 (fr) | 2010-02-01 |
CA2677651A1 (en) | 2008-08-21 |
EP2491923A2 (en) | 2012-08-29 |
US20180289670A1 (en) | 2018-10-11 |
RU2009134223A (ru) | 2011-03-20 |
EP2359818A1 (en) | 2011-08-24 |
ZA200905159B (en) | 2010-05-26 |
CO6220928A2 (es) | 2010-11-19 |
US20150094274A1 (en) | 2015-04-02 |
US20100069458A1 (en) | 2010-03-18 |
US20130029927A1 (en) | 2013-01-31 |
WO2008100985A3 (en) | 2008-10-30 |
PE20090519A1 (es) | 2009-05-29 |
ECSP099576A (es) | 2009-09-29 |
JP2010519209A (ja) | 2010-06-03 |
TN2009000344A1 (en) | 2010-12-31 |
US20170246147A1 (en) | 2017-08-31 |
KR20090110913A (ko) | 2009-10-23 |
EP2120900A2 (en) | 2009-11-25 |
AU2008216327A1 (en) | 2008-08-21 |
CN101626758A (zh) | 2010-01-13 |
WO2008100985A2 (en) | 2008-08-21 |
IL200193A0 (en) | 2010-04-15 |
CL2008000470A1 (es) | 2008-08-29 |
BRPI0807812A2 (pt) | 2020-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065335A1 (es) | Combinaciones de agentes terapeuticos para el tratamiento de cancer | |
Lepetsos et al. | Redox and NF-κB signaling in osteoarthritis | |
Tomasi et al. | S‐adenosyl methionine regulates ubiquitin‐conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers | |
Kumar et al. | Drug targets for cancer treatment: an overview | |
Chan et al. | Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E2 in articular cartilage explants | |
Geisler et al. | Steroid sulfatase inhibitors: promising new tools for breast cancer therapy? | |
Alonso-González et al. | Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis | |
JP2023129662A (ja) | 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法 | |
Horbert et al. | Photoactivatable prodrugs of antimelanoma agent vemurafenib | |
Pieniążek et al. | Oxidative stress induced in rat liver by anticancer drugs doxorubicin, paclitaxel and docetaxel | |
JP2020505395A (ja) | 縮合n−複素環式化合物およびその使用方法 | |
Gao et al. | The therapeutic significance of aromatase inhibitors in endometrial carcinoma | |
EP3573954A1 (en) | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof | |
US20190382377A1 (en) | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer | |
Palacios et al. | Radiosensitization in prostate cancer: mechanisms and targets | |
Ji et al. | K6PC-5, a novel sphingosine kinase 1 (SphK1) activator, alleviates dexamethasone-induced damages to osteoblasts through activating SphK1-Akt signaling | |
Simbulan-Rosenthal et al. | The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma | |
Yang et al. | SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo | |
EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
JP2007505938A5 (es) | ||
NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
Ma et al. | Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |